Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mivelsiran in Early-Stage Down Syndrome-Associated Alzheimer's Disease
NCT07636811Phase 2Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- May 2030
- Countries
- 2
01
Overview
A Phase 2 trial of mivelsiran in Down syndrome-associated Alzheimer's disease (DSAD), sponsored by Alnylam Pharmaceuticals. Started Aug 2026; status: recruiting.
02
Drugs
mivelsiran
03
Conditions
Down syndrome-associated Alzheimer's disease (DSAD)
Beyond the preview
Go deeper on NCT07636811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07636811.